The cancer diagnostics market size has grown rapidly in recent years. It will grow from $25.5 billion in 2025 to $28.58 billion in 2026 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to rising global cancer prevalence, increased investments in oncology research, expansion of hospital diagnostic infrastructure, growing adoption of imaging-based cancer detection, improvements in laboratory automation.
The cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $44.69 billion in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to increasing demand for personalized cancer therapies, rising adoption of next-generation sequencing diagnostics, expansion of population-wide cancer screening programs, growing investments in AI-enabled oncology diagnostics, continuous innovation in multi-cancer detection tests. Major trends in the forecast period include increasing adoption of molecular and companion diagnostics, rising integration of ai in cancer detection, growing use of biomarker-based testing, expansion of high-throughput diagnostic platforms, enhanced focus on early cancer screening.
Rising healthcare expenditure is expected to drive growth in the cancer diagnostics market in the coming years. Healthcare expenditure encompasses the total financial resources allocated to medical treatments, hospital care, medications, and public health initiatives by governments, businesses, and individuals. The growing demand for healthcare spending is largely driven by the increasing prevalence of chronic diseases, which require long-term and often costly care. Higher healthcare expenditure supports cancer diagnostics by enabling the adoption of advanced screening technologies and expanding access to early detection services. Investments in modern equipment and specialized laboratories enhance diagnostic accuracy, facilitate timely intervention, and improve patient outcomes. For example, in May 2024, the UK Office for National Statistics reported that total healthcare expenditure increased by 5.6% in nominal terms in 2023, representing a 0.9% rise compared to 2022. Therefore, rising healthcare expenditure is fueling the growth of the cancer diagnostics market.
The increasing incidence of lung cancer is another key factor driving the cancer diagnostics market. Lung cancer originates in the lung tissues, where abnormal cells grow uncontrollably, forming tumors that may spread to other parts of the body. Cancer diagnostic devices are essential for detecting, diagnosing, and monitoring lung cancer, helping healthcare professionals determine its presence, type, stage, and guide treatment decisions. For instance, in March 2023, the American Society of Clinical Oncology (ASCO), a US-based organization, estimated that 238,340 people in the United States would be diagnosed with lung cancer in 2023, up from 236,000 cases in 2022. Therefore, the rising incidence of lung cancer is contributing to the expansion of the cancer diagnostics market.
Major companies operating in the cancer diagnostics market are focusing on artificial intelligence (AI)-driven innovations to improve diagnostic precision and efficiency. AI-based tools analyze tissue samples and clinical data to aid pathologists in identifying cancerous and non-cancerous regions. For example, in March 2023, Qritive, a Singapore-based developer of AI-powered diagnostic solutions, launched QAi Prostate. This advanced AI-powered tool assists in prostate cancer diagnosis by using machine learning algorithms to accurately detect and classify malignant and benign areas in prostate tissue samples, supporting pathologists in making informed diagnostic and treatment decisions.
Major companies operating in the cancer diagnostics market are Abbott Laboratories, Becton Dickinson and Company, Hologic, GE Healthcare Ltd., Thermo Fisher Scientific, Siemens Healthcare GmbH, Biogenex Laboratories, Veracyte, PathAI, Bio-Rad Laboratories, BioChain, DiagnoCure, Illumina, Myriad Genetics, CompanionDx, Epic Sciences, Genomic Health, Affymetrix, Agilent Technologies, Adaptive Biotechnologies, Biocartis, Biocept, Cancer Genetics Inc., Caris Life Sciences, Cepheid, Epigenomics AG, Exact Sciences, Foundation Medicine, GenMark Diagnostics, Guardant Health, HalioDX, Invitae Corporation, NanoString Technologies, Natera, NeoGenomics, Oncura Inc., PerkinElmer, Personal Genome Diagnostics, Qiagen, Roche Diagnostics.
North America was the largest region in the cancer diagnostics market in 2025. Asia-Pacific was the second-largest region in the global cancer diagnostics market. The regions covered in the cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cancer diagnostics market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Tariffs are influencing the cancer diagnostics market by increasing costs of imported sequencing platforms, imaging systems, reagents, consumables, and laboratory automation equipment. Hospitals, diagnostic laboratories, and research institutes in North America and Europe are most affected due to heavy reliance on imported diagnostic technologies, while Asia-Pacific faces higher procurement costs for advanced testing platforms. These tariffs are raising testing costs and slowing laboratory expansion plans. At the same time, they are encouraging regional manufacturing of diagnostic kits, localized reagent production, and increased focus on cost-efficient diagnostic innovation.
The cancer diagnostics market research report is one of a series of new reports that provides cancer diagnostics market statistics, including cancer diagnostics industry global market size, regional shares, competitors with a cancer diagnostics market share, detailed cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the cancer diagnostics industry. This cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cancer diagnostics involves the processes, tests, and technologies used to detect the presence of cancer in individuals. This area includes various methods aimed at identifying, staging, and characterizing cancer, enabling timely and effective treatment.
The primary offerings within the cancer diagnostics sector include companion diagnostics and molecular diagnostics. Molecular diagnostics involve laboratory procedures to detect particular proteins, genes, or molecules indicating the presence of cancer. Diagnostic methods in cancer assessments encompass biopsies, endoscopies, tumor biomarker tests, and imaging. These diagnostic tools cater to various applications, including cervical cancer, breast cancer, liver cancer, blood cancer, kidney cancer, colorectal cancer, pancreatic cancer, ovarian cancer, melanoma, and others. They are utilized by diverse end-users like cancer research institutes, diagnostic laboratories, hospitals, and related entities.
The cancer diagnostics market consists of sales of pathology-based instruments (slide staining systems, tissue processing systems, cell processors, PCR instruments, NGS instruments, and other pathology-based instruments), imaging Instruments (CT systems, ultrasound systems, MRI systems, mammography systems, and nuclear imaging systems) and biopsy instruments that are used for the diagnosis of cancer. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $44.69 billion in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to increasing demand for personalized cancer therapies, rising adoption of next-generation sequencing diagnostics, expansion of population-wide cancer screening programs, growing investments in AI-enabled oncology diagnostics, continuous innovation in multi-cancer detection tests. Major trends in the forecast period include increasing adoption of molecular and companion diagnostics, rising integration of ai in cancer detection, growing use of biomarker-based testing, expansion of high-throughput diagnostic platforms, enhanced focus on early cancer screening.
Rising healthcare expenditure is expected to drive growth in the cancer diagnostics market in the coming years. Healthcare expenditure encompasses the total financial resources allocated to medical treatments, hospital care, medications, and public health initiatives by governments, businesses, and individuals. The growing demand for healthcare spending is largely driven by the increasing prevalence of chronic diseases, which require long-term and often costly care. Higher healthcare expenditure supports cancer diagnostics by enabling the adoption of advanced screening technologies and expanding access to early detection services. Investments in modern equipment and specialized laboratories enhance diagnostic accuracy, facilitate timely intervention, and improve patient outcomes. For example, in May 2024, the UK Office for National Statistics reported that total healthcare expenditure increased by 5.6% in nominal terms in 2023, representing a 0.9% rise compared to 2022. Therefore, rising healthcare expenditure is fueling the growth of the cancer diagnostics market.
The increasing incidence of lung cancer is another key factor driving the cancer diagnostics market. Lung cancer originates in the lung tissues, where abnormal cells grow uncontrollably, forming tumors that may spread to other parts of the body. Cancer diagnostic devices are essential for detecting, diagnosing, and monitoring lung cancer, helping healthcare professionals determine its presence, type, stage, and guide treatment decisions. For instance, in March 2023, the American Society of Clinical Oncology (ASCO), a US-based organization, estimated that 238,340 people in the United States would be diagnosed with lung cancer in 2023, up from 236,000 cases in 2022. Therefore, the rising incidence of lung cancer is contributing to the expansion of the cancer diagnostics market.
Major companies operating in the cancer diagnostics market are focusing on artificial intelligence (AI)-driven innovations to improve diagnostic precision and efficiency. AI-based tools analyze tissue samples and clinical data to aid pathologists in identifying cancerous and non-cancerous regions. For example, in March 2023, Qritive, a Singapore-based developer of AI-powered diagnostic solutions, launched QAi Prostate. This advanced AI-powered tool assists in prostate cancer diagnosis by using machine learning algorithms to accurately detect and classify malignant and benign areas in prostate tissue samples, supporting pathologists in making informed diagnostic and treatment decisions.
Major companies operating in the cancer diagnostics market are Abbott Laboratories, Becton Dickinson and Company, Hologic, GE Healthcare Ltd., Thermo Fisher Scientific, Siemens Healthcare GmbH, Biogenex Laboratories, Veracyte, PathAI, Bio-Rad Laboratories, BioChain, DiagnoCure, Illumina, Myriad Genetics, CompanionDx, Epic Sciences, Genomic Health, Affymetrix, Agilent Technologies, Adaptive Biotechnologies, Biocartis, Biocept, Cancer Genetics Inc., Caris Life Sciences, Cepheid, Epigenomics AG, Exact Sciences, Foundation Medicine, GenMark Diagnostics, Guardant Health, HalioDX, Invitae Corporation, NanoString Technologies, Natera, NeoGenomics, Oncura Inc., PerkinElmer, Personal Genome Diagnostics, Qiagen, Roche Diagnostics.
North America was the largest region in the cancer diagnostics market in 2025. Asia-Pacific was the second-largest region in the global cancer diagnostics market. The regions covered in the cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cancer diagnostics market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Tariffs are influencing the cancer diagnostics market by increasing costs of imported sequencing platforms, imaging systems, reagents, consumables, and laboratory automation equipment. Hospitals, diagnostic laboratories, and research institutes in North America and Europe are most affected due to heavy reliance on imported diagnostic technologies, while Asia-Pacific faces higher procurement costs for advanced testing platforms. These tariffs are raising testing costs and slowing laboratory expansion plans. At the same time, they are encouraging regional manufacturing of diagnostic kits, localized reagent production, and increased focus on cost-efficient diagnostic innovation.
The cancer diagnostics market research report is one of a series of new reports that provides cancer diagnostics market statistics, including cancer diagnostics industry global market size, regional shares, competitors with a cancer diagnostics market share, detailed cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the cancer diagnostics industry. This cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cancer diagnostics involves the processes, tests, and technologies used to detect the presence of cancer in individuals. This area includes various methods aimed at identifying, staging, and characterizing cancer, enabling timely and effective treatment.
The primary offerings within the cancer diagnostics sector include companion diagnostics and molecular diagnostics. Molecular diagnostics involve laboratory procedures to detect particular proteins, genes, or molecules indicating the presence of cancer. Diagnostic methods in cancer assessments encompass biopsies, endoscopies, tumor biomarker tests, and imaging. These diagnostic tools cater to various applications, including cervical cancer, breast cancer, liver cancer, blood cancer, kidney cancer, colorectal cancer, pancreatic cancer, ovarian cancer, melanoma, and others. They are utilized by diverse end-users like cancer research institutes, diagnostic laboratories, hospitals, and related entities.
The cancer diagnostics market consists of sales of pathology-based instruments (slide staining systems, tissue processing systems, cell processors, PCR instruments, NGS instruments, and other pathology-based instruments), imaging Instruments (CT systems, ultrasound systems, MRI systems, mammography systems, and nuclear imaging systems) and biopsy instruments that are used for the diagnosis of cancer. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Cancer Diagnostics Market Characteristics
3. Cancer Diagnostics Market Supply Chain Analysis
4. Global Cancer Diagnostics Market Trends and Strategies
5. Cancer Diagnostics Market Analysis of End Use Industries
7. Global Cancer Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Cancer Diagnostics Total Addressable Market (TAM) Analysis for the Market
9. Cancer Diagnostics Market Segmentation
10. Cancer Diagnostics Market Regional and Country Analysis
11. Asia-Pacific Cancer Diagnostics Market
12. China Cancer Diagnostics Market
13. India Cancer Diagnostics Market
14. Japan Cancer Diagnostics Market
15. Australia Cancer Diagnostics Market
16. Indonesia Cancer Diagnostics Market
17. South Korea Cancer Diagnostics Market
18. Bangladesh Cancer Diagnostics Market
19. Thailand Cancer Diagnostics Market
20. Vietnam Cancer Diagnostics Market
21. Malaysia Cancer Diagnostics Market
22. Singapore Cancer Diagnostics Market
23. Philippines Cancer Diagnostics Market
24. Hong Kong Cancer Diagnostics Market
25. New Zealand Cancer Diagnostics Market
26. Taiwan Cancer Diagnostics Market
27. South East Asia Cancer Diagnostics Market
28. Western Europe Cancer Diagnostics Market
29. UK Cancer Diagnostics Market
30. Germany Cancer Diagnostics Market
31. France Cancer Diagnostics Market
32. Italy Cancer Diagnostics Market
33. Spain Cancer Diagnostics Market
34. Austria Cancer Diagnostics Market
35. Belgium Cancer Diagnostics Market
36. Denmark Cancer Diagnostics Market
37. Finland Cancer Diagnostics Market
38. Ireland Cancer Diagnostics Market
39. Netherlands Cancer Diagnostics Market
40. Norway Cancer Diagnostics Market
41. Portugal Cancer Diagnostics Market
42. Sweden Cancer Diagnostics Market
42. Switzerland Cancer Diagnostics Market
43. Eastern Europe Cancer Diagnostics Market
44. Russia Cancer Diagnostics Market
45. Czech Republic Cancer Diagnostics Market
46. Poland Cancer Diagnostics Market
47. Romania Cancer Diagnostics Market
48. Ukraine Cancer Diagnostics Market
49. North America Cancer Diagnostics Market
50. USA Cancer Diagnostics Market
51. Canada Cancer Diagnostics Market
52. Mexico Cancer Diagnostics Market
53. South America Cancer Diagnostics Market
54. Brazil Cancer Diagnostics Market
55. Chile Cancer Diagnostics Market
56. Argentina Cancer Diagnostics Market
57. Colombia Cancer Diagnostics Market
58. Peru Cancer Diagnostics Market
59. Middle East Cancer Diagnostics Market
60. Saudi Arabia Cancer Diagnostics Market
61. Israel Cancer Diagnostics Market
62. Iran Cancer Diagnostics Market
63. Turkey Cancer Diagnostics Market
64. United Arab Emirates Cancer Diagnostics Market
65. Africa Cancer Diagnostics Market
66. Egypt Cancer Diagnostics Market
67. Nigeria Cancer Diagnostics Market
68. South Africa Cancer Diagnostics Market
70. Cancer Diagnostics Market Competitive Landscape and Company Profiles
71. Cancer Diagnostics Market Other Major and Innovative Companies
74. Cancer Diagnostics Market High Potential Countries, Segments and Strategies
75. Appendix
List of Tables
Executive Summary
Cancer Diagnostics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cancer diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cancer diagnostics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Products: Companion Diagnostics; Molecular Diagnostics2) By Method: Biopsy; Endoscopy; Tumor Biomarker Tests; Imaging
3) By Application: Cervical Cancer; Breast Cancer; Liver Cancer; Blood Cancer; Kidney Cancer; Colorectal Cancer; Pancreatic Cancer; Ovarian Cancer; Melanoma; Other Applications
4) By End-User: Cancer Research Institutes; Diagnostic Laboratories; Hospitals; Other End Users
Subsegments:
1) By Companion Diagnostics: Biomarker-Based Companion Diagnostics; Genetic Testing-Based Companion Diagnostics; Immunohistochemistry-Based Companion Diagnostics; PCR-Based Companion Diagnostics; Other Companion Diagnostics;2) By Molecular Diagnostics: Polymerase Chain Reaction (PCR) Diagnostics; Next-Generation Sequencing (NGS) Diagnostics; In Situ Hybridization Diagnostics; Microarray-Based Diagnostics; DNA Or RNA Extraction Kits; Other Molecular Diagnostics
Companies Mentioned: Abbott Laboratories; Becton Dickinson and Company; Hologic; GE Healthcare Ltd.; Thermo Fisher Scientific; Siemens Healthcare GmbH; Biogenex Laboratories; Veracyte; PathAI; Bio-Rad Laboratories; BioChain; DiagnoCure; Illumina; Myriad Genetics; CompanionDx; Epic Sciences; Genomic Health; Affymetrix; Agilent Technologies; Adaptive Biotechnologies; Biocartis; Biocept; Cancer Genetics Inc.; Caris Life Sciences; Cepheid; Epigenomics AG; Exact Sciences; Foundation Medicine; GenMark Diagnostics; Guardant Health; HalioDX; Invitae Corporation; NanoString Technologies; Natera; NeoGenomics; Oncura Inc.; PerkinElmer; Personal Genome Diagnostics; Qiagen; Roche Diagnostics
Countries: China; India; Japan; Australia; Indonesia; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; Taiwan; New Zealand; UK; Germany; France; Italy; Spain; Austria; Belgium; Denmark; Finland; Ireland; Netherlands; Norway; Portugal; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Cancer Diagnostics market report include:- Abbott Laboratories
- Becton Dickinson and Company
- Hologic
- GE Healthcare Ltd.
- Thermo Fisher Scientific
- Siemens Healthcare GmbH
- Biogenex Laboratories
- Veracyte
- PathAI
- Bio-Rad Laboratories
- BioChain
- DiagnoCure
- Illumina
- Myriad Genetics
- CompanionDx
- Epic Sciences
- Genomic Health
- Affymetrix
- Agilent Technologies
- Adaptive Biotechnologies
- Biocartis
- Biocept
- Cancer Genetics Inc.
- Caris Life Sciences
- Cepheid
- Epigenomics AG
- Exact Sciences
- Foundation Medicine
- GenMark Diagnostics
- Guardant Health
- HalioDX
- Invitae Corporation
- NanoString Technologies
- Natera
- NeoGenomics
- Oncura Inc.
- PerkinElmer
- Personal Genome Diagnostics
- Qiagen
- Roche Diagnostics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 28.58 Billion |
| Forecasted Market Value ( USD | $ 44.69 Billion |
| Compound Annual Growth Rate | 11.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 41 |
